EurekAlert! Cancer Research - News Releases

News Releases

Updates every hour. Last Updated: 9-Jul-2025 12:10 ET (9-Jul-2025 16:10 GMT/UTC)

Canine genes offer clues to gastric cancer in humans

Cornell University
Peer-Reviewed Publication

A team of Cornell researchers used canine DNA to uncover more than 15 genes linked to gastric cancer.

Journal: Proceedings of the National Academy of Sciences

Clinical validation of a circulating tumor DNA–based blood test to screen for colorectal cancer

JAMA Network
Peer-Reviewed Publication

About The Study: In an average-risk colorectal cancer screening population, a blood-based test demonstrated acceptable accuracy for colorectal cancer detection, but detection of advanced precancerous lesions remains a challenge, and ongoing efforts are needed to improve test sensitivity.

Journal: JAMA

Screening colonoscopy yields among adults ages 45 to 49 after lowering the colon cancer screening age

JAMA Network
Peer-Reviewed Publication

About The Study: The finding of a slightly lower prevalence of any adenoma in the younger compared with the older age group (35.4% vs 40.8%) in the current study is consistent with an evaluation of 2001 screening colonoscopies from a university-based medical center between 2019 and 2021, which reported slightly lower rates of adenoma detection in those ages 45 to 49 vs 50 to 54 (34.3% vs 38.2%) and with a large study of adenoma detection rates in those ages 45 to 49 vs 50 to 54 (28.6% vs 31.8%) who underwent a screening colonoscopy before the change in guidelines (i.e., 2014-2020).

Journal: JAMA

Pre-operative THP leads to a pCR in two-thirds of early-stage HER2+ ER- breast cancer patients

ECOG-ACRIN Cancer Research Group
Reports and Proceedings

Patients with early-stage HER2+ breast cancer typically receive pre-operative multi-agent chemotherapy and anti-HER2 antibodies, followed by surgery and possibly more chemotherapy. The CompassHER2 pCR trial is evaluating a less intensive, reduced chemotherapy approach, the first large-scale study of its kind, but more follow-up is needed to assess its impact on survival. Meanwhile, researchers are reporting rates of pathologic complete response (pCR) at time of surgery, detailing which patients are most likely to benefit from the new approach.

Funder: NIH/National Cancer Institute, Breast Cancer Research Foundation, Susan G. Komen

E-cigarette warnings lower vaping interest and raise quit intentions

University of North Carolina Health Care
Peer-Reviewed Publication

E-cigarette warnings, especially those highlighting health harms, effectively discourage vaping without causing unintended consequences like increased cigarette smoking, according to a meta-analysis of 24 studies by University of North Carolina Lineberger Comprehensive Cancer Center researchers and their colleagues.

Journal: JAMA Internal Medicine
Funder: NIH/National Institute on Drug Abuse, Center for Tobacco Products

Adding immunotherapy to standard chemotherapy extends quality of life for patients with advanced endometrial cancer

University of California - Los Angeles Health Sciences
Peer-Reviewed Publication

A UCLA-led study found that combining the immunotherapy drug dostarlimab with standard chemotherapy not only provides a meaningful improvement in survival for patients with advanced endometrial cancer, but also improves the quality of that extended survival by minimizing the time spent suffering from disease symptoms or severe treatment side effects.

Journal: International Journal of Gynecological Cancer

Electronic health record intervention boosts fertility preservation for young adult cancer patients

Temple University Health System
Reports and Proceedings

A new study from researchers at Fox Chase Cancer Center released at the American Society of Clinical Oncology’s (ASCO) Annual Meeting demonstrates that a simple addition to the electronic medical record (EMR) system can assist fertility preservation efforts for young adult cancer patients.

Meeting: 2025 ASCO Annual Meeting

New drug combination increases overall survival in patients with PIK3CA-mutated advanced breast cancer

Mass General Brigham
Peer-Reviewed Publication

In a randomized clinical trial, Mass General Brigham researchers and their colleagues found that combining inavolisib with the standard two-drug treatment resulted in longer patient survival and slower cancer progression for those with the PIK3CA gene mutation.

Journal: New England Journal of Medicine
Funder: F. Hoffmann-La Roche, NIH/National Cancer Institute
Meeting: 2025 ASCO Annual Meeting

Study provides new insights into the genetic complexity of cancer metastasis

Memorial Sloan Kettering Cancer Center
Peer-Reviewed Publication

A new study from researchers at MSK and Weill Cornell Medicine provides fresh insights about how cancers evolve when they metastasize — insights that could aid in developing strategies to improve the effectiveness of treatment.

Journal: Nature Genetics
Funder: NIH/National Cancer Institute

Clairity becomes the first FDA-authorized AI platform for breast cancer prediction – historic milestone for women’s health

LaVoieHealthScience
Business Announcement

Clairity, Inc., a digital health innovator advancing AI-driven healthcare solutions, has received U.S. Food and Drug Administration (FDA) De Novo authorization for CLAIRITY BREAST, a novel, image-based prognostic platform designed to predict five-year breast cancer risk from a routine screening mammogram. With this authorization, Clairity is planning to launch among leading health systems through 2025 – propelling a new era of precision medicine in breast cancer.

42
43
44
45
46